Intense rehabilitation therapy produces very large gains in chronic stroke. by Cramer, Steven C
UC Irvine
UC Irvine Previously Published Works
Title
Intense rehabilitation therapy produces very large gains in chronic stroke.
Permalink
https://escholarship.org/uc/item/441545pb
Journal
Journal of neurology, neurosurgery, and psychiatry, 90(5)
ISSN
0022-3050
Author
Cramer, Steven C
Publication Date
2019-05-01
DOI
10.1136/jnnp-2019-320441
License
CC BY 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
497Cramer SC. J Neurol Neurosurg Psychiatry May 2019 Vol 90 No 5
Intense rehabilitation therapy produces 
very large gains in chronic stroke
Steven C Cramer
A Call to Arm Rehabilitation to End Neuro-Nihilism
Stroke is among the top three causes 
of disability in our species. Motor defi-
cits are the most common problem after 
stroke and a major contributor to this 
disability. Activity-based training (e.g., 
physical therapy or occupational therapy) 
can improve behavioural outcomes, with 
meta-analysis suggesting that higher 
doses of activity-based therapy targeting 
the motor system improve behavioural 
outcomes after stroke.1 However, many 
patients do not receive high doses of reha-
bilitation therapy after stroke, for reasons 
that include economic factors, access, and 
a paucity of data to guide decision-making 
regarding therapy intensity.
In this context, Ward et al2 exam-
ined whether providing patients with a 
very large dose of rehabilitation therapy 
produces enduring gains in motor func-
tion, with critically important results. 
These authors enrolled 224 patients in 
the chronic phase of stroke (median 18 
months post-stroke). Entry criteria were 
intentionally broad: stroke survivors were 
eligible if they had a weak (but not para-
lyzed) arm and were excluded if pain, 
spasticity, or medical conditions were 
severe. Each received 90 hours of therapy 
over 3-weeks, consisting of an individu-
alized program of occupational therapy 
and physical therapy that aimed to reduce 
impairment and improve activities of daily 
living through improved motor control.
All patients completed the 3-week 
programme, with no adverse events 
reported. Statistically significant and 
clinically important motor gains were 
found for all four co-primary arm motor 
outcome measures. For example, the 
Action Research Arm Test (ARAT) score 
increased by a median of 6 points from 
pre-therapy to post-therapy (minimal clin-
ically important difference=5.7 points). 
Critically, behavioural gains not only 
persisted after end of therapy but also 
continued to grow. By 6 months post-
therapy, ARAT had increased 2 more 
points and gains exceeded the minimal 
clinically important difference in 61.6% 
of patients.
Behavioural gains in this study were 
high, comparing quite favourably with 
any published data in the history of stroke 
recovery research. Other strengths of the 
study include its very large size and enrol-
ment of patients with wide-ranging motor 
deficits. The study is limited by the absence 
of a control group, although arm func-
tion generally plateaus by 3 months post-
stroke. Enrollees (median age 52) were 
young for stroke, and global functional 
status was very good (median Barthel 
Index score of 19 out of 20), suggesting 
uncertainty as to how results will gener-
alise to patients with severe global deficits.
These positive results will forever 
change how research into activity-based 
training after stroke is dosed: 90 hours of 
therapy improves arm function while 32 
hours3 does not. Results suggest the need 
for a health economic analysis. In this 
regard, telehealth methods might be able 
to efficiently extend application of these 
results.4 Stroke is not a ‘one-size-fits-all’ 
target, and so the target population that 
responds best to this intervention should 
be defined. Ward et al found baseline 
behaviour to be a useful predictor, but 
direct measures of neural injury and neural 
function are powerful predictors of treat-
ment response in patients with chronic 
stroke and often outperform behavioural 
assessments.5
We owe it to our patients to provide 
therapies that substantially improve 
functional status. The nihilistic view that 
chronic stroke is a condition that cannot 
be improved with therapy is no longer 
tenable. The question is not whether we 
can substantially improve function in a 
majority of our patients, but rather what is 
the best pathway to deliver this care.
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